ALLMedicine™ Acute Megakaryoblastic Leukemia Center
Research & Reviews 86 results
https://doi.org/10.1182/blood.2021011463
Blood Hasle H, Kline RM et. al.
Nov 11th, 2021 - Individuals with Down syndrome are at increased risk of myeloid leukemia in early childhood associated with acquisition of GATA1 mutations that generate a short GATA1 isoform called GATA1s. Germline GATA1s generating mutations result in congenital...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394903
Blood Jann JC, Tothova Z
Jun 23rd, 2021 - Cohesin is a multisubunit protein complex that forms a ring-like structure around DNA. It is essential for sister chromatid cohesion, chromatin organization, transcriptional regulation, and DNA damage repair and plays a major role in dynamically s...
https://clinicaltrials.gov/ct2/show/NCT02530619
May 26th, 2021 - PRIMARY OBJECTIVES: I. Determine the safety profile of alisertib in patients with acute megakaryoblastic leukemia (AMKL) and in patients with myelofibrosis (MF). SECONDARY OBJECTIVES: I. Determine preliminary efficacy of alisertib in both populati...
https://doi.org/10.1007/s12185-020-03066-7 10.1182/blood-2008-11-163501 10.1182/blood-2007-01-069542 10.1182/blood-2005-06-2448 10.1182/blood-2007-10-118810 10.1111/j.1365-2141.2008.07231.x 10.1182/blood.V80.6.1521.1521 10.1016/0046-8177(91)90111-2 10.1007/s12185-013-1487-5 10.1111/bjh.15390 10.1182/blood-2003-02-0390 10.1182/blood-2010-05-282426 10.1038/bmt.2012.244 10.1182/blood-2013-07-515148 10.1002/ajmg.a.61748
International Journal of Hematology; Yamato G, Park MJ et. al.
Jan 5th, 2021 - Transient abnormal myelopoiesis (TAM) is a unique clonal myeloproliferation characterized by immature megakaryoblasts that occurs in 5-10% of neonates with Down syndrome (DS). Although TAM regresses spontaneously in most patients, approximately 20...
https://doi.org/10.1016/j.clml.2020.11.001
Clinical Lymphoma, Myeloma & Leukemia; Wang Y, Lu A et. al.
Dec 2nd, 2020 - Acute megakaryoblastic leukemia (AMKL) is a biologically heterogeneous subtype of acute myeloid leukemia that originates from megakaryocytes. Patients with AMKL with non-Down syndrome (DS) had a poorer prognosis. However, clear prognostic indicato...
Clinicaltrials.gov 2 results
https://clinicaltrials.gov/ct2/show/NCT02530619
May 26th, 2021 - PRIMARY OBJECTIVES: I. Determine the safety profile of alisertib in patients with acute megakaryoblastic leukemia (AMKL) and in patients with myelofibrosis (MF). SECONDARY OBJECTIVES: I. Determine preliminary efficacy of alisertib in both populati...
https://clinicaltrials.gov/ct2/show/NCT02056782
Feb 16th, 2015 - This is an open-label, multi-center, 10 patient pilot study with an anticipated 1 year enrollment period Primary Objectives: To evaluate the safety and tolerability of ODSH in patients with Acute Myeloid Leukemia (AML) receiving cytarabine and ida...
News 1 results
https://www.mdedge.com/hematology-oncology/article/188547/leukemia-myelodysplasia-transplantation/team-identifies-new-mechanism
HT Staff
Jan 13th, 2016 - Megakaryocytes in the bone marrow Investigators have discovered a new mechanism of megakaryocyte differentiation, according to a paper published in eLife. They found that overexpression of the methyltransferase enzyme PRMT1 in acute megakaryocytic.
